Wells Fargo’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-116,487
Closed -$6.11M 7442
2020
Q3
$6.11M Sell
116,487
-80,208
-41% -$3.32M ﹤0.01% 2332
2020
Q2
$6.54M Sell
196,695
-32,543
-14% -$1.04M ﹤0.01% 2216
2020
Q1
$6.24M Buy
229,238
+43,324
+23% +$1.21M ﹤0.01% 2061
2019
Q4
$3.67M Buy
185,914
+122,996
+195% +$1.97M ﹤0.01% 2838
2019
Q3
$815K Buy
62,918
+8,597
+16% +$104K ﹤0.01% 4002
2019
Q2
$677K Sell
54,321
-78,377
-59% -$1.04M ﹤0.01% 4172
2019
Q1
$1.93M Buy
132,698
+10,114
+8% +$129K ﹤0.01% 3389
2018
Q4
$1.35M Sell
122,584
-114,067
-48% -$1.59M ﹤0.01% 3606
2018
Q3
$6.22M Buy
236,651
+8,710
+4% +$235K ﹤0.01% 2472
2018
Q2
$4.66M Sell
227,941
-9,542
-4% -$205K ﹤0.01% 2753
2018
Q1
$4.31M Sell
237,483
-10,466
-4% -$174K ﹤0.01% 2754
2017
Q4
$3.46M Buy
247,949
+28,429
+13% +$384K ﹤0.01% 2914
2017
Q3
$4.06M Buy
219,520
+13,921
+7% +$233K ﹤0.01% 2707
2017
Q2
$3.48M Buy
205,599
+11,789
+6% +$179K ﹤0.01% 2743
2017
Q1
$2.59M Sell
193,810
-16,380
-8% -$257K ﹤0.01% 2994
2016
Q4
$3.16M Buy
210,190
+44,197
+27% +$584K ﹤0.01% 2773
2016
Q3
$1.94M Sell
165,993
-7,192
-4% -$84.6K ﹤0.01% 2993
2016
Q2
$1.87M Buy
173,185
+29,181
+20% +$301K ﹤0.01% 3028
2016
Q1
$1.33M Buy
144,004
+33,704
+31% +$363K ﹤0.01% 3214
2015
Q4
$1.64M Buy
110,300
+85,813
+350% +$1.44M ﹤0.01% 3136
2015
Q3
$402K Sell
24,487
-3,930
-14% -$80.4K ﹤0.01% 4085
2015
Q2
$649K Buy
28,417
+18,998
+202% +$378K ﹤0.01% 3926
2015
Q1
$143K Buy
9,419
+4,452
+90% +$57.8K ﹤0.01% 4586
2014
Q4
$60K Sell
4,967
-39,191
-89% -$448K ﹤0.01% 4947
2014
Q3
$501K Buy
44,158
+31,224
+241% +$356K ﹤0.01% 3897
2014
Q2
$156K Buy
12,934
+12,734
+6,367% +$150K ﹤0.01% 4488
2014
Q1
$2K Hold
200
﹤0.01% 5711
2013
Q4
$4K Sell
200
-100
-33% -$1.68K ﹤0.01% 5440
2013
Q3
$4K Hold
300
﹤0.01% 5352
2013
Q2
$5K Buy
+300
New +$3.96K ﹤0.01% 5227

Wells Fargo's MNTA Position: Q4 2020 in Review

Wells Fargo sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 116,487 shares — an estimated $6.11M sold.

Wells Fargo first reported a position in MNTA in Q2 2013 and held it in 30 quarters. The position peaked at $6.54M in Q2 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.

  • Wells Fargo reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Wells Fargo sold 116,487 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $6.11M.
  • Wells Fargo first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 30 quarters.
  • Wells Fargo's Momenta Pharmaceuticals, Inc. position peaked at $6.54M in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.

Based on Wells Fargo's 13F filing for Q4 2020, filed 9 Feb 2021.